C12Y 114/16002
Tyrosine 3-monooxygenase
Official title: Tyrosine 3-monooxygenase (1.14.16.2)
C12Y114/16002 (Tyrosine 3-monooxygenase) appears on 39 US grants and 49 published applications in this corpus.
Search patents in C12Y- Granted patents
- 39
- Published applications
- 49
- Assignees
- 40
- Inventors
- 107
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 2 |
| 2003 | 2 | 3 |
| 2004 | 1 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 2 |
| 2016 | 1 | 0 |
| 2017 | 2 | 2 |
| 2018 | 0 | 2 |
| 2019 | 2 | 4 |
| 2020 | 4 | 5 |
| 2021 | 1 | 3 |
| 2022 | 2 | 6 |
| 2023 | 0 | 3 |
| 2024 | 2 | 2 |
| 2025 | 5 | 6 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition for regulating production of interfering ribonucleic acid13 Jan 2026US 12,522,830 B2Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid18 Nov 2025US 12,473,552 B2Wyvern Pharmaceuticals Inc.
- Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof16 Sep 2025US 12,416,029 B2Antheia, Inc.
- Recombinant host cells with improved production of L-DOPA, dopamine, S-noroclaurine or derivatives thereof29 Jul 2025US 12,371,722 B2River Stone Biotech Aps
- Genetic construct3 Jun 2025US 12,319,927 B2Healing Genes LLC
- Methods for producing modified betalains in yeast3 Sep 2026US 2026/0258343 A1Danmarks Tekniske Universitet
- Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof7 May 2026US 2026/0125725 A1Antheia, Inc.
- Gene sequence construct used for treatment of central nervous system diseases30 Apr 2026US 2026/0117234 A1
- Recombinant host cells with improved production of l-dopa, dopamine, s-noroclaurine or derivatives thereof25 Dec 2025US 2025/0388939 A1River Stone Biotech Aps
- Genetic Construct2 Oct 2025US 2025/0305001 A1Healing Genes LLC
Most cited
By later US patents
- Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system353US 5,082,670 AThe Regents of the University of California · 1992
- AAV-mediated delivery of DNA to cells of the nervous system222US 6,180,613 B2The Rockefeller University · 2001
- In vitro induction of dopaminergic cells88US 5,981,165 ANeurospheres Holdings Ltd. · 1999
- AAV-mediated delivery of DNA to cells of the nervous system81US 6,503,888 B1The Rockefeller University · 2003
- Methods of treating Parkinson's disease using recombinant adeno-associated virus virions69US 7,588,757 B2Genzyme Corporation · 2009